Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Summary

A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine (Vidaza®) in intermediate-2 and high risk MDS patients.

Timeline

Start

2011-07-05

Primary completion

2011-12

Completion

2015-11-16

Drugs

Indications